{"id":"NCT01479530","sponsor":"H. Lundbeck A/S","briefTitle":"Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2011-11-24","resultsPosted":"2014-06-26","lastUpdate":"2018-09-10"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Azilect®","otherNames":["Rasagiline"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Azilect®","type":"EXPERIMENTAL"}],"summary":"The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese patients with motor fluctuations. Azilect® (Rasagiline) is indicated for the treatment of idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.","primaryOutcome":{"measure":"Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary","timeFrame":"Baseline and Weeks 4, 8, 12, and 16","effectByArm":[{"arm":"Placebo","deltaMin":-0.76,"sd":0.16},{"arm":"Azilect®","deltaMin":-1.25,"sd":0.16}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0228"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":18,"countries":["China"]},"refs":{"pmids":["29988514"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":158},"commonTop":["Dyskinesia"]}}